Skip to main content

Table 1 Applied biomarker panel

From: Multiparameter analysis of homogeneously R-CHOP-treated diffuse large B cell lymphomas identifies CD5 and FOXP1 as relevant prognostic biomarkers: report of the prospective SAKK 38/07 study

Marker

Source/clone

Pretreatment

Dilution

Incubation

Other

Cutoff (AUROC or reference)

bcl2

Ventana/Roche 790-4604

CC1 16′

RTU

12′

 

70 % [34, 46]

bcl6

Ventana/Roche 760-4241

CC1 32′

RTU

28′

 

30 % [30]

c-myc

Ventana/Roche 790-4628

CC1 92′

RTU

16′, 37 °C

 

40 % [34, 46]

CD5

Ventana/Roche 790-4451

CC1 24′

RTU

12′

 

20 % (0.542)

CD10

Ventana/Roche 790-4506

CC1 24′

RTU

16′

 

20 % [29]

CD95

Leica NCL-FAS-310

PC 120 °C, 3′, citrate buffer pH 6

1:400

60′, 20 °C

 

1 % (0.613)

CD168

Leica NCL-CD168

CC1 extended 92′

1:200

32′

Biotin blocker

10 % (0.536)

Amplification

Cyclin E

Thermo MS-1060-S

MW 98 °C, 30′, citrate buffer pH 6

1:20

Overnight, 4 °C

 

12 % (0.669)

FOXP1

Ventana/Roche 760-4611

CC1 16′

RTU

12′

 

50 % [45]

GCET

Abcam Ab68889

CC1 32′

1:25

20′

 

60 % [29]

LMO2

Ventana/Roche 790-4368

CC1 32′

RTU

16′

 

30 % [29]

MUM1p

Ventana/Roche 760-4529

CC1 24′

RTU

16′

 

70 % [29]

pSTAT3

Cell Signaling 9145

MW 98 °C, 30′, TEC buffer pH 8

1:50

Overnight, 4 °C

Biotin blocker

17 % (0.602)

BCL2 BAP

Abbott/Vysis 07 J75-001

Exactly as described [31]

>3 % [31]

C-MYC BAP

Abbott/Vysis 05 J91-001

>4 % [31]

MYC/IGH DFP

Abbott/Vysis 05 J75-001

>6.5 % [31]

EBER

Ventana/Roche 760-1209

According to the manufacturer’s protocol

10 %

  1. For diagnostic purposes and to “subtract” CD3-positive T cells in CD5-positive DLBCL, CD3 and CD20 stainings were also performed, but these were not considered biomarkers sensu stricto